aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants [Yahoo! Finance]
aTyr Pharma, Inc. (LIFE)
Last atyr pharma, inc. earnings: 3/26 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
atyrpharma.com/investors-media
Company Research
Source: Yahoo! Finance
Company initiating program based on blinded EFZO-FIT ™ study investigator and patient participant feedback. SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced plans to initiate an Individual Patient Expanded Access Program (EAP) for its lead therapeutic candidate, efzofitimod, for patients with pulmonary sarcoidosis. The Individual Patient EAP is intended to allow access for patients who complete the Phase 3 EFZO-FIT™ study and wish to receive treatment with efzofitimod outside of the clinical trial. “We are pleased to make efzofitimod available to patients beyond the duration of the EFZO-FIT™ clinical trial through this Individual Patient EAP,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “Based on interest from Principal Inv
Show less
Read more
Impact Snapshot
Event Time:
LIFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LIFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LIFE alerts
High impacting aTyr Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
LIFE
News
- aTyr Pharma, Inc. (NASDAQ: LIFE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.MarketBeat
- aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate UpdateGlobeNewswire
- aTyr Pharma Insiders Placed Bullish Bets Worth US$514.6k [Yahoo! Finance]Yahoo! Finance
- aTyr Pharma to Participate in April Investor ConferencesGlobeNewswire
LIFE
Earnings
- 3/14/24 - Miss
LIFE
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- 4/5/24 - Form ARS
- LIFE's page on the SEC website